Phase I trial of high dose nitazoxanide, 1500mg twice daily, with 14 participants. Trreatment was safe and well tolerated. PBPK predictions were confirmed on day 1 but with underprediction at day 5. Median Cmin was above the in vitro
target concentration on first dose and maintained throughout. NCT04746183
Walker et al., 9/11/2021, preprint, 32 authors.